Bolt Biotherapeutics, Inc.
BOLT
$3.68
-$0.18-4.71%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -80.77% | -98.96% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -80.77% | -98.96% | |||
| Cost of Revenue | 12.25% | -8.04% | |||
| Gross Profit | -12.78% | -83.32% | |||
| SG&A Expenses | -13.44% | -10.23% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.73% | -5.90% | |||
| Operating Income | 0.46% | -35.61% | |||
| Income Before Tax | -6.57% | -9.24% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -6.57% | -9.24% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -6.57% | -9.24% | |||
| EBIT | 0.46% | -35.61% | |||
| EBITDA | 0.04% | -38.28% | |||
| EPS Basic | -5.93% | -12.29% | |||
| Normalized Basic EPS | 5.15% | -44.55% | |||
| EPS Diluted | -5.93% | -12.29% | |||
| Normalized Diluted EPS | 5.15% | -44.55% | |||
| Average Basic Shares Outstanding | 0.60% | -2.71% | |||
| Average Diluted Shares Outstanding | 0.60% | -2.71% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||